Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: J Neurooncol. 2019 Jul 19;144(2):403–407. doi: 10.1007/s11060-019-03243-7

Table 2:

Grade 3 toxicities

Toxicity N %
Hyperglycemia 4 13
Hypophosphatemia 2 7
Lymphopenia 2 7
Neutropenia 1 3
Increased alanine aminotransferase 1 3

Adverse events possibly, probably, or definitely attributed to perifosine, per patient (n=30)